ITMCTR2200005632尚未招募未知
Randomized controlled trial and metabolomic mechanism of Lingbao Huxin Pill in the treatment of stable angina (Qi deficiency and blood stasis syndrome)
适应症
试验速览
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 性别
- All
入选标准
- •1.Inclusion criteria for the stable angina group
- •(1) Meet the western medical diagnostic standards for stable type angina of coronary heart disease;
- •(2) Meet the TCM dialectical standards for qi deficiency and blood stasis;
- •(3) Patients with angina attacks 2 or more times a week;
- •(4) The Canadian Cardiovascular Society (CCS) graded angina with gradeS I.-III.;
- •(5) Age 18-80 years old (including 18 and 80 years old);
- •(6) Sign the informed consent form.
- •2.Criteria for inclusion in the acute myocardial infarction group
- •(1) Meet the diagnostic criteria of Western medicine for acute myocardial infarction;
- •(2) Meet the TCM dialectical standards for qi deficiency and blood stasis;
- •(3) The onset time is less than 6 hours, and the coronary angiography is confirmed by emergency coronary angiography to confirm the single, double or triple vascular lesions of the coronary arteries and PCI;
- •(4) Age 18-80 years old (including 18 and 80 years old);
- •(5) Sign an informed consent form.
- •3.Inclusion criteria for health groups
- •(1) Determined to be in good health by the Physical Examination Center of Shuguang Hospital;
- •(2) Meet the physical and mental health standards determined by the WHO;
- •(3) Age 18-80 years old (including 18 and 80 years old);
- •(4) Sign the informed consent form.
排除标准
- •(1) Pregnant, planned pregnancy or lactating women;
- •(2) Those with serious cardiovascular diseases such as refractory heart failure, cardiogenic shock, and severe valvular heart disease;
- •(3) Chest pain caused by lesions other than coronary artery disease, such as psychosis, severe neurosis, hyperthyroidism, biliary syndrome, gastric and esophageal reflux, aortic dissection, etc.;
- •(4) Complicated with uncontrolled grade III hypertension (systolic blood pressure = 180mmHg and/or diastolic blood pressure =110mmHg), severe arrhythmias;
- •(5) Severe respiratory diseases such as severe pulmonary insufficiency (PaO2<60mmHg).
- •(6) Patients with severe liver and kidney diseases such as hepatic insufficiency (the level of alanine aminotransferase or aspartate aminotransferase is more than 2 times higher than normal), renal insufficiency (creatinine level is more than 2 times higher than normal);
- •(7) There are other serious diseases or conditions such as malignant tumors, severe anemia, and severe renal artery stenosis;
- •(8) Patients who are allergic to the components of the test drug and have severe allergic constitutions;
- •(9) Those who have participated in clinical research of other drugs in the past 2 months;
- •(10) Recently, researchers with infections, traumas, etc. have judged that they cannot participate in the study.
研究者
相似试验
招募中
3 期
Metabolic effects of adding Topiramate on Aripiprazole in bipolar patients under age 18IRCT20200606047668N1Esfahan University of Medical Sciences38
撤回
3 期
Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on CancerOverall SurvivalCancerNCT02201381Health Clinics Limited
招募中
1 期
Study the effect of CAPRIDIN in the metabolic treatment of drug-resistant epilepsyIRCT20170315033086N11Shahid Beheshti University of Medical Sciences10
尚未招募
不适用
Multicenter trial of effects for glucometabolism, platelet activation marker and inflammatory marker by single or combinathin therapy with tofogliflozin and anagliptin in type 2 diabetic patientstype 2 diabetes mellitusJPRN-UMIN000028634Kansai Medical University100
已完成
不适用
Randomized, controlled trial of the clinical effect of selecrive SGLT2 blocker, ipragliflozin, and DPP-4 blocker in type 2 diabetic patients with NAFLD/NASH.- multicenter studytype 2 diabetic patients with NAFLD/NASHJPRN-UMIN000015727Saga University55
